Type 2 diabetes (T2D) is a chronic disorder that can lead to a high disease burden and repeated hospital admissions due to its ability to facilitate a multitude of subsequent morbidities.1 Conventional studies often focus on investigating the risk of time-to-first events in T2D patients, giving limi

According to the American Diabetes Association (ADA)/ European Association for the Study of Diabetes (EASD) guideline, a patient-centered approach to type 2 diabetes (T2D) management should be adopted with the goal of not only preventing complications but also optimizing patients’ quality of life.¹ To achieve these goals, factors that affect health-related quality of life (HRQoL) such as social determinants of health, psychosocial well-being, and health behaviors are key considerations in glycemic management strategies for patients with T2D.¹ At the EASD Annual Meeting 2023, Professor Chan, Chung-Ngor Juliana from the Department of Medicine and Therapeutics, The Chinese University of Hong Kong presented the results of a cross-sectional analysis of HRQoL in patients with T2D treated with oral glucose-lowering drugs (OGLDs) who were enrolled in the Joint Asia Diabetes Evaluation (JADE) Register. In a subsequent interview with Omnihealth Practice, Prof. Chan shared further insights on the application of the JADE® Program, shedding light on the dynamics between glycemic management strategies and patients’ HRQoL.

Bariatric surgeries have been previously shown to improve glycemic control and may even lead to remission among patients with diabetes. While gastric bypass (GBP) used to be the most preferred surgical method, sleeve gastrectomy (SG) has been gaining popularity in recent years. As such, researcher

Non-alcoholic fatty liver (NAFLD) is the most common chronic liver disorder increasing morbidity and mortality worldwide with cardiovascular disease (CVD) being the main cause of death.¹ Recent findings from a meta-analysis of observational studies demonstrated an increased cardiovascular risk with NAFLD, especially with advanced fibrosis.² Therefore, with several studies highlighting this association, it may be important to consider cardiovascular screening in NAFLD patients in addition to the management of liver disease due to its potential in decreasing the disease burden.³

Weight control remains an indispensable component for the clinical management of type 2 diabetes mellitus (T2DM) in preventing cardiometabolic morbidity.1-3 People with T2DM who received weekly subcutaneous injection of semaglutide 2.4mg achieved superior and clinically meaningful reduction of body

Fatty liver encompasses broad spectrum of conditions that lead to accumulation of fat in the liver. In Asia, the prevalence of non-alcoholic fatty liver disease (NAFLD) and its subsets are increasing due to altered dietary habits and lifestyle factors.¹

Vitamin D deficiency has been reported in at least 1 billion people worldwide, while 50% of the population has vitamin D insufficiency.¹ Vitamin D deficiency arises from multiple causes including inadequate diet and insufficient exposure to sunlight.²

The increased prevalence of type 2 diabetes mellitus (T2DM) may cause an increase in chronic kidney disease burden.¹ Sodium-glucose cotransporter 2 (SGLT2) inhibitors are used to lower blood glucose levels in patients with T2DM,

Self-monitoring blood glucose (SMBG) is an integral part of self-management in patients with type 1 diabetes. However, the use of SMBG in patients with type 2 diabetes has caused some debates in the field.

Canagliflozin is the first sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes.1 Although canagliflozin offers benefits such as reductions in body weight, blood pressure, and risk for hypoglycemia,2 the US Food and Drug Administration (FDA) has included a